Get the Stockscreener App
1.645
2.81%
0.045
Aprea Therapeutics Inc stock is traded at $1.645, with a volume of 41,193.
It is up +2.81% in the last 24 hours and down -20.91% over the past month.
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
See More
Previous Close:
$1.60
Open:
$1.65
24h Volume:
41,193
Relative Volume:
0.85
Market Cap:
$9.58M
Revenue:
-
Net Income/Loss:
$-14.29M
P/E Ratio:
-0.4123
EPS:
-3.99
Net Cash Flow:
$-12.27M
1W Performance:
-2.66%
1M Performance:
-20.91%
6M Performance:
-37.21%
1Y Performance:
-56.13%
1-Day Range:
$1.56
$1.70
1-Week Range:
$1.56
$1.75
52-Week Range:
$1.412
$5.01
Aprea Therapeutics Inc Stock (APRE) Company Profile
Name
Aprea Therapeutics Inc
Sector
Industry
Phone
215-948-4119
Address
3805 OLD EASTON ROAD, DOYLESTOWN, MA
Compare APRE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APRE
Aprea Therapeutics Inc
|
1.645 | 9.61M | 0 | -14.29M | -12.27M | -3.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aprea Therapeutics Inc Stock (APRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-28-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | Berenberg | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Jun-22-20 | Initiated | H.C. Wainwright | Neutral |
| Apr-21-20 | Initiated | Robert W. Baird | Outperform |
| Oct-28-19 | Initiated | JP Morgan | Neutral |
| Oct-28-19 | Initiated | Morgan Stanley | Equal-Weight |
| Oct-28-19 | Initiated | RBC Capital Mkts | Outperform |
View All
Aprea Therapeutics Inc Stock (APRE) Latest News
Aprea Therapeutics Inc.’s volatility index tracking explainedInsider Buying & Reliable Momentum Entry Alerts - Newser
Tick level data insight on Aprea Therapeutics Inc. volatilityJuly 2025 Snapshot & Daily Profit Focused Screening - Newser
What’s the recovery path for long term holders of Aprea Therapeutics Inc.July 2025 Selloffs & Precise Swing Trade Alerts - Newser
Short interest data insights for Aprea Therapeutics Inc.2025 Fundamental Recap & Weekly High Momentum Picks - Newser
Pattern recognition hints at Aprea Therapeutics Inc. upsideQuarterly Profit Review & Safe Investment Capital Preservation Plans - Newser
Using Ichimoku Cloud for Aprea Therapeutics Inc. technicalsWeekly Trend Report & Breakout Confirmation Alerts - Newser
Is Aprea Therapeutics Inc. stock entering bullish territoryBond Market & Entry Point Confirmation Signals - Newser
Aprea Therapeutics Inc. Shows Early Signs of Technical StrengthDollar Strength & Low Drawdown Momentum Ideas - Newser
Will a bounce in Aprea Therapeutics Inc. offer an exit2025 Trading Recap & Precise Trade Entry Recommendations - Newser
Market reaction to Aprea Therapeutics Inc.’s recent newsMarket Movement Recap & Consistent Profit Trading Strategies - Newser
Should you hold or exit Aprea Therapeutics Inc. nowJuly 2025 Earnings & Reliable Volume Spike Alerts - Newser
What’s next for Aprea Therapeutics Inc. stock priceWeekly Loss Report & Risk Adjusted Swing Trade Ideas - Newser
Exit strategy if you’re trapped in Aprea Therapeutics Inc.Gap Up & Smart Allocation Stock Tips - Newser
Key resistance and support levels for Aprea Therapeutics Inc.Quarterly Trade Summary & Verified Short-Term Plans - Newser
Volatility clustering patterns for Aprea Therapeutics Inc.Weekly Trend Recap & High Conviction Buy Zone Picks - Newser
Is Aprea Therapeutics Inc. building a consolidation baseJuly 2025 Setups & Expert Curated Trade Setups - Newser
How hedge fund analytics apply to Aprea Therapeutics Inc. stockJuly 2025 Snapshot & Advanced Swing Trade Entry Plans - Newser
Aprea Therapeutics Inc. stock retracement – recovery analysisWeekly Trade Recap & Low Risk Profit Maximizing Plans - Newser
Detecting support and resistance levels for Aprea Therapeutics Inc.July 2025 Earnings & Safe Capital Growth Tips - Newser
How to interpret RSI for Aprea Therapeutics Inc. stockQuarterly Earnings Summary & Free Weekly Watchlist of Top Performers - Newser
Is now a turning point for Aprea Therapeutics Inc.Trade Volume Summary & Short-Term High Return Ideas - Newser
Trend analysis for Aprea Therapeutics Inc. this weekMarket Growth Summary & AI Driven Stock Price Forecasts - Newser
Long term hold vs stop loss in Aprea Therapeutics Inc.Bond Market & Capital Efficiency Focused Ideas - Newser
Analyzing drawdowns of Aprea Therapeutics Inc. with statistical toolsJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
Full technical analysis of Aprea Therapeutics Inc. stockQuarterly Portfolio Report & Real-Time Volume Analysis - Newser
Signal strength of Aprea Therapeutics Inc. stock in tech scanners2025 Geopolitical Influence & Accurate Buy Signal Alerts - Newser
Should I average down on Aprea Therapeutics Inc. stockWeekly Gains Report & Real-Time Buy Zone Alerts - sundaytimes.kr
Aprea Reports Positive Early Cancer Trial Results, Maintains Cash Runway Into 2026 - MSN
Is Aprea Therapeutics Inc. Stock Overbought or Oversold RSI Indicator AnalysisTrade Risk Summary & Weekly High Potential Stock Alerts - Newser
Has Aprea Therapeutics Inc. found a price floorMarket Weekly Review & Weekly Top Stock Performers List - Newser
Analyzing recovery setups for Aprea Therapeutics Inc. investorsRate Cut & Fast Exit and Entry Trade Guides - Newser
Is Aprea Therapeutics Inc. a momentum stockJuly 2025 Retail & Long-Term Safe Investment Ideas - 선데이타임즈
Aprea Therapeutics Inc Stock (APRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aprea Therapeutics Inc Stock (APRE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Duey Marc | Director |
Oct 18 '24 |
Sale |
4.58 |
6,462 |
29,583 |
233,651 |
| Gilad Oren | President/CEO |
Oct 23 '24 |
Buy |
3.92 |
500 |
1,958 |
333,395 |
| Duey Marc | Director |
Oct 16 '24 |
Buy |
4.39 |
30,000 |
131,700 |
240,113 |
| Gilad Oren | President/CEO |
Oct 15 '24 |
Buy |
2.90 |
250 |
725 |
332,895 |
| Duey Marc | Director |
Oct 14 '24 |
Buy |
2.58 |
190 |
490 |
210,113 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 11 '24 |
Buy |
2.46 |
50 |
123 |
19,368 |
| Seizinger Bernd R. | Director |
Oct 11 '24 |
Buy |
2.68 |
10,000 |
26,800 |
44,730 |
| Gilad Oren | President/CEO |
Oct 14 '24 |
Buy |
2.59 |
1,000 |
2,590 |
332,645 |
| Gilad Oren | President/CEO |
Oct 10 '24 |
Buy |
2.54 |
150 |
381 |
331,645 |
| Hamill John P. | SrVP/CFO/Prin Fin & Acct Ofcr |
Oct 10 '24 |
Buy |
2.61 |
450 |
1,174 |
19,318 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):